Today 7:50 AM ET (MarketWatch)
NEW YORK (MarketWatch) -- The U.S. Food and Drug Administration has approved a new drug by Merck (MRK) that lowers the risk of heart attacks and cardiovascular events associated with peripheral arterial disease. The new drug, Zontivity, was found to reduce rates of death from cardiovascular trauma by 17% over the three years it was studied. "A significant number of Americans who have survived a heart attack or who have PAD remain at risk for another major cardiovascular event despite the use of existing treatments," said Eugene Braunwald, M.D., who supervised the FDA's study of the drug. "A new treatment option like Zontivity is an important advance that can help to lower that risk for appropriate patients taking aspirin, clopidogrel, or both." Merck's shares were flat during premarket trading Monday.
-Joseph Adinolfi; 415-439-6400; AskNewswires@dowjones.com
(END) Dow Jones Newswires
May 12, 2014 07:50 ET (11:50 GMT)
Copyright (c) 2014 Dow Jones & Company, Inc.
No comments:
Post a Comment